# A Phase 2 Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203)

> **NCT03563599** · PHASE2 · COMPLETED · sponsor: **Qurient Co., Ltd.** · enrollment: 60 (actual)

## Conditions studied

- Treatment-naïve, Sputum Smear-positive Patients With Drug-sensitive Pulmonary TB

## Interventions

- **DRUG:** Telacebec (Q203)
- **DRUG:** Rifafour e-275

## Key facts

- **NCT ID:** NCT03563599
- **Lead sponsor:** Qurient Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-23
- **Primary completion:** 2019-09-09
- **Final completion:** 2019-09-09
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2019-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03563599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03563599, "A Phase 2 Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03563599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*